Literature DB >> 24397813

Nifedipine-sensitive blood pressure component in hypertensive models characterized by high activity of either sympathetic nervous system or renin-angiotensin system.

J Zicha1, Z Dobešová, M Behuliak, M Pintérová, J Kuneš, I Vaněčková.   

Abstract

High blood pressure (BP) of spontaneously hypertensive rats (SHR) is maintained by enhanced activity of sympathetic nervous system (SNS), whereas that of Ren-2 transgenic rats (Ren-2 TGR) by increased activity of renin-angiotensin system (RAS). However, both types of hypertension are effectively attenuated by chronic blockade of L-type voltage-dependent calcium channel (L-VDCC). The aim of our study was to evaluate whether the magnitude of BP response elicited by acute nifedipine administration is proportional to the alterations of particular vasoactive systems (SNS, RAS, NO) known to modulate L-VDCC activity. We therefore studied these relationships not only in SHR, in which mean arterial pressure was modified in a wide range of 100-210 mm Hg by chronic antihypertensive treatment (captopril or hydralazine) or its withdrawal, but also in rats with augmented RAS activity such as homozygous Ren-2 TGR, pertussis toxin-treated SHR or L-NAME-treated SHR. In all studied groups the magnitude of BP response to nifedipine was proportional to actual BP level and it closely correlated with BP changes induced by acute combined blockade of RAS and SNS. BP response to nifedipine is also closely related to the degree of relative NO deficiency. This was true for both SNS- and RAS-dependent forms of genetic hypertension, suggesting common mechanisms responsible for enhanced L-VDCC opening and/or their upregulation in hypertensive animals. In conclusions, BP response to nifedipine is proportional to the vasoconstrictor activity exerted by both SNS and RAS, indicating a key importance of these two pressor systems for actual L-VDCC opening necessary for BP maintenance.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24397813

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  7 in total

Review 1.  Interplay between the renin-angiotensin system, the canonical WNT/β-catenin pathway and PPARγ in hypertension.

Authors:  Alexandre Vallée; Bernard L Lévy; Jacques Blacher
Journal:  Curr Hypertens Rep       Date:  2018-06-09       Impact factor: 5.369

2.  Both central sympathoexcitation and peripheral angiotensin II-dependent vasoconstriction contribute to hypertension development in immature heterozygous Ren-2 transgenic rats.

Authors:  Lenka Řezáčová; Ivana Vaněčková; Silvie Hojná; Anna Vavřínová; Pavol Valovič; Hana Rauchová; Michal Behuliak; Josef Zicha
Journal:  Hypertens Res       Date:  2021-10-08       Impact factor: 3.872

3.  Cooperation of augmented calcium sensitization and increased calcium entry contributes to high blood pressure in salt-sensitive Dahl rats.

Authors:  Josef Zicha; Michal Behuliak; Anna Vavřínová; Zdenka Dobešová; Jaroslav Kuneš; Hana Rauchová; Ivana Vaněčková
Journal:  Hypertens Res       Date:  2021-04-19       Impact factor: 3.872

4.  Effects of Salvia sclarea on chronic immobilization stress induced endothelial dysfunction in rats.

Authors:  Hyo Jung Yang; Ka Young Kim; Purum Kang; Hui Su Lee; Geun Hee Seol
Journal:  BMC Complement Altern Med       Date:  2014-10-14       Impact factor: 3.659

Review 5.  The Gut Microbiota in Cardiovascular Disease and Arterial Thrombosis.

Authors:  Anna Lässiger-Herfurth; Giulia Pontarollo; Alexandra Grill; Christoph Reinhardt
Journal:  Microorganisms       Date:  2019-12-13

6.  Development and Validation of a Novel Nomogram to Predict the Risk of Intervertebral Disc Degeneration.

Authors:  Fudong Li; Xiaofei Sun; Yuan Wang; Lu Gao; Jiangang Shi; Kaiqiang Sun
Journal:  Mediators Inflamm       Date:  2022-09-10       Impact factor: 4.529

7.  Sympathectomy-induced blood pressure reduction in adult normotensive and hypertensive rats is counteracted by enhanced cardiovascular sensitivity to vasoconstrictors.

Authors:  Anna Vavřínová; Michal Behuliak; Michal Bencze; Martin Vodička; Peter Ergang; Ivana Vaněčková; Josef Zicha
Journal:  Hypertens Res       Date:  2019-09-17       Impact factor: 3.872

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.